You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Moodys
Colorcon
Express Scripts
Dow

Last Updated: February 28, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,155,069

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,155,069
Title:Bone graft with a tannin-hydroxyapatite scaffold and stem cells for bone engineering
Abstract: A biocompatible bone graft for implanting into a bone wound site or screening a bone disease drug, comprising a porous scaffold structure made from a tannin-hydroxyapatite resin, a population of osteocompetent stem cells, and a growth medium. Methods of synthesis and physical characterization of the porous scaffold structure are described, as well as biological testing of the osteocompetent stem cells of the bone graft.
Inventor(s): Abdalla; Soliman Mahmoud Soliman (Jeddah, SA), Al-Marzouki; Fahad (Jeddah, SA), Pizzi; Antonio (Epinal, FR), Bahabri; Fatma Salem (Jeddah, SA)
Assignee: King Abdulaziz University (Jeddah, SA)
Application Number:15/261,037
Patent Claims:1. A biocompatible bone graft comprising: a porous scaffold structure comprising a tannin-hydroxyapatite resin which has a 17-80 vol % porosity, a pore diameter of 40-300 .mu.m, and a compressive strength of 0.15-1.90 MPa; a population of osteocompetent stem cells obtained from a mammalian donor; and a growth medium.

2. The biocompatible bone graft of claim 1, wherein the tannin-hydroxyapatite resin comprises 50-90 wt % tannin and 10-50 wt % hydroxyapatite.

3. The biocompatible bone graft of claim 1, wherein the osteocompetent stem cells are derived from a sample of bone marrow, periosteum, dermal fibroblasts, or adipose tissue.

4. The biocompatible bone graft of claim 1, wherein at least 50% of the osteocompetent stem cells express CD13, CD29, CD44, CD90, or CD105.

5. The biocompatible bone graft of claim 1 further comprising a growth factor.

6. The biocompatible bone graft of claim 5 wherein the growth factor is at least one selected from the group consisting of .beta.-glycerophosphate, dexamethasone, ascorbic acid, transforming growth factor .beta. (TGF-.beta..sub.1), fibroblast growth factor (FGF), active vitamin D, a bone morphogenic protein (BMP), and parathyroid hormone.

7. The biocompatible bone graft of claim 1 further comprising adsorbed or chemically-linked osteoinductive biomolecules on the surface of the porous scaffold structure.

8. The biocompatible bone graft of claim 1 wherein the porous scaffold structure further comprises at least one biodegradable polymer selected from the group consisting of poly lactic-co-glycolic acid, poly lactic acid, poly glycolic acid, polyanhydride, poly(ortho)ester, polyurethane, poly(butyric acid), poly(valeric acid), polycaprolactone, poly(lactide-co-caprolactone), and poly(trimethylene carbonate).

9. The biocompatible bone graft of claim 1, intended to be placed in a bone wound site in a patient, the bone wound site comprising: a first portion of bone on a first side of the porous scaffold structure; and a second portion of bone on a second side of the porous scaffold structure.

10. The biocompatible bone graft of claim 9 further comprising a mineralized osseous tissue supported by the porous scaffold structure and connecting the first portion of bone with the second portion of bone.

11. The biocompatible bone graft of claim 9 wherein the patient is the mammalian donor.

12. The biocompatible bone graft of claim 1 further comprising a prosthesis.

13. The biocompatible bone graft of claim 1 further comprising a second biocompatible bone graft wherein the second biocompatible bone graft has a different size, shape, and/or composition.

14. A method of monitoring the biocompatible bone graft of claim 1 present within a bone wound site in a patient, the method comprising monitoring the growth of the osteocompetent stem cells up to 16 weeks by X-ray imaging, MRI, or ultrasonography.

15. A method of monitoring the biocompatible bone graft of claim 1 present within a bone wound site in a patient, the method comprising monitoring the growth of the osteocompetent stem cells up to 16 weeks by the expression level of at least one osteogenic differentiation gene selected from the group consisting of RUNX2, COL1A1, ALPL, OPN, and PDGFRB.

16. A method of screening a bone disease drug comprising: adding the bone disease drug to the biocompatible bone graft of claim 1; growing the osteocompetent stem cells in the presence of the bone disease drug to form a treated biocompatible bone graft having a new bone tissue; measuring the porosity, density, and/or compressive strength of the treated biocompatible bone graft; and comparing the porosity, density, and/or compressive strength of the treated biocompatible bone graft to a biocompatible bone graft of claim 1 that has not been treated with the bone disease drug.

17. The method of claim 16 wherein the bone disease drug is denosumab, teriparatide, alendronate, risedronate, ibandronate, zoledronic acid, teriparatide, strontium ranelate, aluminium chlorohydrate, or odanacatib.

18. A method of making a porous scaffold structure comprising: mixing porous tannin powder particles, dried polyethylene glycol particles, and hydroxyapatite to form a powder mixture; mixing the powder mixture with an organic acid and a formaldehyde solution to form a liquid mixture; incubating the liquid mixture to form a set scaffold; and heating the set scaffold to remove the polyethylene glycol particles to form the porous scaffold structure.

19. The method of claim 18 wherein the powder mixture further comprises a biodegradable polymer.

20. The method of claim 19 wherein the biodegradable polymer is at least one selected from poly lactic-co-glycolic acid, poly lactic acid, poly glycolic acid, polyanhydride, poly(ortho)ester, polyurethane, poly(butyric acid), poly(valeric acid), polycaprolactone, poly(lactide-co-caprolactone), and poly(trimethylene carbonate).

Details for Patent 10,155,069

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Start Trial King Abdulaziz University (Jeddah, SA) 2039-02-26 RX Orphan search
Amgen XGEVA denosumab INJECTABLE; SUBCUTANEOUS 125320 002 2010-06-01   Start Trial King Abdulaziz University (Jeddah, SA) 2039-02-26 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial King Abdulaziz University (Jeddah, SA) 2039-02-26 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial King Abdulaziz University (Jeddah, SA) 2039-02-26 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial King Abdulaziz University (Jeddah, SA) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Moodys
Express Scripts
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.